AbbVie's ducks get in a row as Galapagos reports promising RA data
This article was originally published in Scrip
Executive Summary
Galapagos' oral JAK1 inhibitor filgotinib (GLPG0634) has met the primary and other endpoints in an important Phase IIb study in rheumatoid arthritis. The news will also be welcomed by AbbVie, which is partnered with Galapagos for the drug.